Document:

THIS
PROMISSORY NOTE HAS BEEN ACQUIRED FOR INVESTMENT AND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
QUALIFIED UNDER ANY STATE SECURITIES LAWS. THIS PROMISSORY NOTE MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION
OR QUALIFICATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

 

DEMAND
PROMISSORY NOTE

 

	XXXXXXXX	XXXXXXX
	 	New York, New York

 

FOR
VALUE RECEIVED, Grandparents.Com, Inc., a Delaware corporation (the “Company”), promises to pay to the
order of XXXXXX or his registered assigns (the “Holder”), the principal sum of XXXX with interest compounded
annually on the outstanding principal amount at the rate of ten percent (10%) per annum (computed on the basis of actual calendar
days elapsed and a year of 365 days) or, if less, at the highest rate of interest then permitted under applicable law (the “Applicable
Rate”). Interest shall commence with the date hereof and shall continue on the outstanding principal of this Promissory
Note (this “Note”) until paid in accordance with the provisions hereof. Notwithstanding the foregoing (and
for the avoidance of doubt), interest on this Note shall not be due and payable until the Maturity Date (as defined below). For
purposes of this Note, “Business Day” means any day on which banks in New York, New York are generally open
for business.

 

1.Maturity.
Unless sooner paid in accordance with the terms hereof, the entire unpaid principal amount and all unpaid accrued interest under
this Note shall become fully due and payable on demand or upon the acceleration of the maturity of this Note by the Holder upon
the occurrence of an Event of Default (such earlier date, the “Maturity Date”). 

 

Event
of Default. The occurrence of any of the following shall be an “Event of Default”: (i) any material
default by the Company of any material agreement to which the Company is a party to; (ii) the failure by the Company to pay any
material obligation as such obligation becomes due and payable; or (iii) the failure by the Company to pay the Holder all amount
due and payable under this Note on the Maturity Date. Upon the occurrence of any Event of Default, the Holder shall be entitled
to receive from the Company the maximum amount of interest payable by law from the original date of this Note to the date of payment.

 

2.Prepayment.
The Company shall have the right to prepay, upon five (5) Business Days written notice to the Holder, any amounts owed under this
Note in whole or in part at any time without the prior written consent of the Holder.

 

3.Lost,
Stolen, Destroyed or Mutilated Notes. In case this Note shall be mutilated, lost, stolen or destroyed, the Company shall issue
a new note of like date, tenor and denomination and deliver the same in exchange and substitution for and upon surrender and cancellation
of such mutilated Note, or in case this Note is lost, stolen or destroyed, upon receipt of evidence satisfactory to the Company
of the loss, theft or destruction of such Note.

 

4.Governing
Law. This Note is to be construed in accordance with and governed by the laws of the State of New York, without giving effect
to the conflict of laws principles thereof. 

 

5.Amendment
and Waiver. Any term of this Note may be amended and the observance of any term of this Note may be waived (either generally
or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Holder.
Any amendment or waiver effected in accordance with this Section 5 shall be binding upon the Company and the Holder.

 

    	 

    	 

    

 

 

6.Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Note must be
in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile or e-mail (provided confirmation of transmission is mechanically or electronically generated and kept on file by
the sending party); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified,
in each case, properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications
shall be: 

 

If
to the Company:

XXXXXXXXXXXXXX

If
to the Holder:

XXXXXXXXXXXXXXXX

7.Severability.
If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from
this Note and the balance of this Note shall be interpreted as if such provision were so excluded and shall be enforceable in
accordance with its terms.

 

8.Assignment.
The Company shall not have the right to assign its rights and obligations hereunder or any interest herein. 

 

9.Remedies
Cumulative; Failure or Indulgence Not a Waiver. The remedies provided in this Note shall be cumulative and in addition to
all other remedies available under this Note. No failure or delay on the part of the Holder in the exercise of any power, right
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any other right, power or privilege.

 

10.Payments.
Whenever any payment of cash is to be made by the Company to the Holder pursuant to this Note, such payment shall be made in lawful
money of the United States of America by a check drawn on the account of the Company and sent via overnight courier service to
the Holder at such address as previously provided to the Company in writing (which address, in the case of the Holder as of the
date of issuance hereof, shall initially be the address for the Holder as set forth in Section 6 hereof); provided that the Holder
may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with not less
than two (2) Business Days prior written notice setting out such request and the Holder’s wire transfer instructions. Whenever
any payment to be made shall otherwise be due on a day that is not a Business Day, such payment shall be made on the immediately
succeeding Business Day and such extension of time shall be included in the computation of accrued interest.

 

11.Excessive
Interest. Notwithstanding any other provision herein to the contrary, this Note is hereby expressly limited so that the interest
rate charged hereunder shall at no time exceed the maximum rate permitted by applicable law. If, for any circumstance whatsoever,
the interest rate charged exceeds the maximum rate permitted by applicable law, the interest rate shall be reduced to the maximum
rate permitted, and if the Holder shall have received an amount that would cause the interest rate charged to be in excess of
the maximum rate permitted, such amount that would be excessive interest shall be applied to the reduction of the principal amount
owing hereunder (without charge for prepayment) and not to the payment of interest, or if such excessive interest exceeds the
unpaid balance of principal, such excess shall be refunded to the Company.

 

12.Waiver
of Notice. To the extent permitted by law, the Company hereby waives demand, notice, protest and all other demands and notices
in connection with the delivery, acceptance, performance, default or enforcement of this Note.

  

IN
WITNESS WHEREOF, the Company has caused this Note to be duly executed by its officers, thereunto duly authorized as of the
date first above written.

 

	 	GRANDPARENTS.COM, INC.
	 	 
	 	By: 	/s/ Steven
    Leber
	 	 	Steven
    Leber
Chairman & Co-CEOEXHIBIT 10.1

 

EXECUTION VERSION

 

	SunTrust Robinson Humphrey, Inc.	 	JEFFERIES FINANCE LLC	 	MORGAN STANLEY SENIOR 
	SunTrust Bank	 	520 Madison Avenue	 	FUNDING, INC
	3333 Peachtree Road	 	New York, New York 10022	 	1585 Broadway
	Atlanta, Georgia 30326	 	 	 	New York, New York 10036

 

June 16, 2013

 

BioScrip, Inc.

100 Clearbrook Road

Elmsford,
New York 10523

Attention:     Hai
Tran, Chief Financial Officer

 

BioScrip, Inc.

$475,000,000 Senior Credit Facilities

Commitment Letter

 

Ladies and Gentlemen:

 

BioScrip,
Inc., a Delaware corporation (the “Company”), has advised SunTrust Bank, SunTrust Robinson Humphrey,
Inc. (“STRH” and, together with SunTrust Bank, “SunTrust”), Jefferies Finance
LLC (“Jefferies”), and Morgan Stanley Senior Funding, Inc. (“Morgan Stanley”)
that the Company proposes to acquire (the “Acquisition”) substantially all of the assets of a company
previously identified to us as “Cassidy” (such assets, collectively, the “Acquired Business”)
from CarePoint Partners Holdings LLC, a Delaware limited liability company (“CarePoint”), and the direct
and indirect subsidiaries of CarePoint set forth on the signature pages to the Acquisition Agreement (as defined below; CarePoint
and such subsidiaries, collectively, “Seller”). The Acquisition will be effected pursuant to an
asset purchase agreement (together with all addendums, exhibits, and schedules thereto, collectively, the “Acquisition
Agreement”) among the Company, the Seller, the members of CarePoint set forth on the signature pages thereto, and
the other parties thereto. All references to “Company” or “Company and its subsidiaries” for any period
from and after consummation of the Acquisition shall include the Acquired Business.

 

In connection with the foregoing, the Company
has advised SunTrust, Jefferies, and Morgan Stanley that it intends to raise $475,000,000 senior secured first lien credit facilities
comprised of (a) a senior secured first lien revolving credit facility in an aggregate amount of $75,000,000 (the “Revolving
Credit Facility”), (b) a senior secured first lien term loan B in an aggregate amount of $250,000,000 (the “Term
Loan B Facility”), and (c) a senior secured first lien delayed draw term loan B in an aggregate amount of $150,000,000
(the “Delayed Draw Term Loan Facility”; the Revolving Credit Facility, the Term Loan B Facility, and
the Delayed Draw Term Loan Facility, collectively, the “Senior Credit Facilities”), for the purposes
of (i) funding a portion of the Acquisition consideration and repaying certain existing indebtedness related to the Acquired Business
(other than Permitted Surviving Debt (as defined below)) (the “Acquired Business Refinancing”), (ii)
refinancing certain existing indebtedness of the Company and its subsidiaries (other than Permitted Surviving Debt) (the “Refinancing”),
(iii) funding other permitted acquisitions and paying fees and expenses incurred in connection therewith, (iv) financing capital
expenditures and working capital needs of the Company and its subsidiaries, (v) funding other general corporate purposes of the
Company and its subsidiaries, and (vi) paying fees and expenses incurred in connection with the Senior Credit Facilities and the
other Transactions (as defined below).

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 2

 

As used herein, the
term “Transactions” means the Acquisition, the Acquired Business Refinancing, the Refinancing, the entering
into of this Commitment Letter and the Fee Letters (as defined below), the entering into of the Senior Credit Facilities and the
initial borrowings thereunder, and the payment of fees and expenses in connection with each of the foregoing. The closing date
of the initial funding of the Senior Credit Facilities (other than the Delayed Draw Term Loan Facility) and the Refinancing (the
“Closing Date”) shall be a date mutually agreed upon between the Company and the Lead Arrangers (as defined
below), but in any event shall not occur until all of the conditions (but solely those conditions) set forth in Section C of this
Commitment Letter and the section entitled “Conditions to Closing and Initial Borrowing” in the Term Sheet have been
satisfied or waived. The closing date of the initial funding of the Delayed Draw Term Loan Facility, the Acquisition and the Acquired
Business Refinancing (the “Delayed Draw Date”) shall be a date mutually agreed upon between the Company
and the Lead Arrangers, but in any event shall not occur until all of the conditions (but solely those conditions) set forth in
the section entitled “Conditions to Delayed Draw Term Loan” in the Term Sheet have been satisfied or waived.

 

The parties hereto
previously entered into that certain commitment letter dated as of May 22, 2013 (the “Existing Commitment Letter”),
with respect to the Senior Credit Facilities. The parties hereto agree that this commitment letter supersedes the Existing Commitment
Letter in its entirety and SunTrust, Jefferies, and Morgan Stanley shall have no obligations under the Existing Commitment Letter.

 

		A.	Commitment

 

Each
of SunTrust Bank, Jefferies, and Morgan Stanley (collectively, the “Initial Lenders”) is pleased to commit
to provide 512⁄3%, 262⁄3%, and 212⁄3%, respectively, of the aggregate principal amount of the Senior Credit
Facilities to the Company, subject to the terms and conditions set forth in this commitment letter and in the Summary of Principal
Terms and Conditions attached hereto as Exhibit A (the “Term Sheet” and, together with this commitment
letter, the “Commitment Letter”) and such other terms and conditions as are not inconsistent with the
terms and conditions set forth herein and therein and as the Company and the Lead Arrangers may agree. Capitalized terms used in
this commitment letter but not defined herein shall have the meanings given to them in the Term Sheet. The commitments and all
other obligations of SunTrust, Jefferies, and Morgan Stanley under this Commitment Letter shall be several and not joint.

 

		B.	Syndication

 

The Initial Lenders
have, subject to the terms and conditions hereof, provided a commitment for 100% of the aggregate principal amount of the Senior
Credit Facilities and, promptly upon execution of this Commitment Letter, the Initial Lenders and STRH intend to commence efforts
to syndicate to one or more lenders (collectively, including the Initial Lenders, the “Lenders”) all
or any portion of the commitments of the Initial Lenders hereunder to provide the Senior Credit Facilities to the Company on the
terms and conditions set forth in this Commitment Letter; provided that the commitments of the Initial Lenders hereunder,
the availability of the Senior Credit Facilities (other than the Delayed Draw Term Loan Facility) on the Closing Date and the availability
of the Delayed Draw Term Loan Facility on the Delayed Draw Date are not subject to the consummation or completion of such syndication
or the achievement of a Successful Syndication (as defined in the Lead Arranger Fee Letter).

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 3

 

The Company hereby
appoints SunTrust Bank to act, and SunTrust Bank agrees to act, as sole administrative agent for the Senior Credit Facilities,
subject to the terms and conditions of this Commitment Letter. The Company hereby appoints (i) STRH, Jefferies, and Morgan Stanley
to act, and STRH, Jefferies, and Morgan Stanley agree to act, as joint lead arrangers and joint bookrunners (collectively, the
“Lead Arrangers”) for the Senior Credit Facilities, (ii) Jefferies to act, and Jefferies agrees to act,
as syndication agent for the Senior Credit Facilities, and (iii) Morgan Stanley to act, and Morgan Stanley agrees to act, as documentation
agent for the Senior Credit Facilities, in each case, subject to the terms and conditions of this Commitment Letter. STRH will
have the “left” and “highest” placement in any and all marketing materials and documentation used in connection
with the Senior Credit Facilities and will have responsibilities typically associated with the “left” and “highest”
placement. Jefferies will have “right” placement, in all cases immediately to the right of STRH, in any and all marketing
materials and documentation used in connection with the Senior Credit Facilities and have responsibilities typically associated
with “right” placement. Morgan Stanley will have “right” placement, in all cases immediately to the right
of Jefferies, in any and all marketing materials and documentation used in connection with the Senior Credit Facilities and have
responsibilities typically associated with “right” placement. STRH, in consultation with the Company, will manage all
aspects of the syndication of the Senior Credit Facilities, including the timing of all offers to potential Lenders, the determination
of all amounts offered to potential Lenders, the selection of Lenders in consultation with the Company, the allocation of commitments
among the Lenders, and the determination of compensation and titles (such as co-agent, managing agent, etc.), if any, to be given
such Lenders; provided that any titles conferred (other than administrative agent), and compensation offered, shall be as
agreed by the Lead Arrangers; provided further that, in connection with the syndication of the Senior Credit Facilities,
the Lead Arrangers will not offer the opportunity to acquire a commitment, and the Lenders shall not assign any of their respective
commitments under the Senior Credit Facilities, in each case, so long as no event of default under the Financing Documentation
(as defined below) is in existence, to (a) the banks, financial institutions or other institutional lenders set forth on Exhibit
B attached hereto or (b) any entity competing with the Company or any of its subsidiaries in the infusion and home health services
business that has been specified by name by the Company to STRH in writing at least three days prior to the retail lender meeting
for the Senior Credit Facilities (each, a “Competitor” and, together with the entities described in clause
(a), the “Disqualified Institutions”). The Company agrees that (x) no other agents, co-agents or arrangers
will be appointed or other titles conferred, (y) no other agents, co-agents or arrangers will receive any arrangement fee or other
compensation for arranging or syndicating the Senior Credit Facilities, except as expressly set forth in the Lead Arranger Fee
Letter (as defined below), and (z) no Lender will receive any compensation for its commitment to, or participation in, the Senior
Credit Facilities except as expressly set forth in the Term Sheet and the Fee Letters (as defined below), in each case, unless
agreed by the Lead Arrangers.

 

The Lead Arrangers
intend to commence syndication efforts promptly following the execution of the Commitment Letter. Until the earlier of a Successful
Syndication and the day that is 60 days following the Closing Date, the Company agrees to, and agrees to use its commercially reasonable
efforts to cause the Seller to, actively assist the Lead Arrangers in syndicating the Senior Credit Facilities and take all action
as the Lead Arrangers may reasonably request related to providing such assistance. The Company’s assistance shall include:
(i) making (and using commercially reasonable efforts to cause the Seller to make) senior management and representatives of the
Company, the Seller and their respective subsidiaries available to participate in one meeting with potential Lenders and, to the
extent reasonably requested, one or more conference calls in addition to such meeting; (ii) using commercially reasonable efforts
to ensure that the syndication effort benefits from the existing lending relationships of the Company, and the Seller; (iii) assisting
in the preparation and completion of a reasonable and customary confidential information memorandum regarding the Company, the
Acquired Business, the Senior Credit Facilities, and the other Transactions (the “CIM”) and other customary
marketing materials to be used in connection with the syndication of the Senior Credit Facilities, in form and substance mutually
acceptable to the Lead Arrangers and the Company; (iv) preparing and providing (and using commercially reasonable efforts to cause
the Seller to prepare and provide) promptly to the Lead Arrangers all customary and reasonable information with respect to the
Company, the Acquired Business, the Seller, their respective subsidiaries, and the Transactions including without limitation financial
projections (the “Projections”) and other financial information, reasonably requested by the Lead Arrangers
in connection with the syndication of the Senior Credit Facilities (subject, in the case of any business or legal diligence materials,
to customary non-disclosure and non-reliance letters reasonably acceptable to the Lead Arrangers and the party providing such diligence
materials); and (v) using commercially reasonable efforts to obtain credit ratings of the Senior Credit Facilities and the corporate
family credit of the Company by Standard & Poor’s Rating Group, a division of The McGraw-Hill Companies, Inc. (“S&P”),
and Moody’s Investor Service, Inc. (“Moody’s”).

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 4

 

If requested, you also
will assist us in preparing an additional version of Information (as defined below) and Projections (together with Information,
collectively, “Borrower Materials”) (the “Public-Side Version”) to be used
by prospective Lenders’ public-side employees and representatives (“Public-Siders”) who do not
wish to receive material non-public information (within the meaning of United States federal securities laws) with respect to the
Company, the Acquired Business, the Seller, their respective affiliates and any of their respective securities (“MNPI”)
and who may be engaged in investment and other market related activities with respect to the Company’s, the Seller’s,
or their respective affiliates’ securities or loans. Before distribution of any Borrower Materials, you agree to execute
and deliver to us (i) a letter in which you authorize distribution of the Borrower Materials to a prospective Lender’s employees
willing to receive MNPI (“Private-Siders”) and (ii) a separate letter in which you authorize distribution
of the Public-Side Version to Public-Siders and represent that no MNPI is contained therein. You acknowledge and agree that the
following documents may be distributed to Public-Siders (unless you notify us prior to their intended distribution that any such
document contains MNPI): (a) drafts identified by the Company as not containing MNPI, drafts and final definitive documentation
with respect to the Senior Credit Facilities (the “Financing Documentation”), and drafts and final versions
of the Acquisition Agreement; (b) customary administrative materials prepared by the Lead Arrangers for prospective Lenders (such
as a lender meeting invitation, allocations and funding and closing memoranda); and (c) notification of changes in the terms of
the Senior Credit Facilities. You also agree, at the request of the Lead Arranger, to identify that portion of any other Borrower
Materials to be distributed to Public-Siders, including by clearly and conspicuously marking such materials “PUBLIC”
which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof. By marking
Borrower Materials “PUBLIC”, you shall be deemed to have authorized SunTrust Bank, the Lead Arrangers, and the proposed
Lenders to treat such Borrower Materials as not containing any MNPI with respect to you and your subsidiaries, any of your or their
respective securities or the transactions contemplated hereby for the purpose of United States federal and state securities laws.

 

To ensure an orderly and effective syndication
of the Senior Credit Facilities, the Company agrees that, until the earliest to occur of (i) 60 days after the Closing Date, (ii)
the date on which a Successful Syndication is achieved, and (iii) the date of termination of this Commitment Letter pursuant to
Section G.1 below, as applicable, the Company will not, and will not permit its subsidiaries to, arrange, sell, syndicate or issue,
attempt to arrange, sell, syndicate or issue, announce or authorize the announcement of the arrangement, sale, syndication or issuance
of, or engage in discussions concerning the arrangement, sale, syndication or issuance of, any credit facilities or debt security
(including any renewals thereof) except (a) with the prior written consent of STRH, (b) the Senior Credit Facilities, (c) replacements,
extensions and renewals of existing indebtedness of the Company and its subsidiaries that matures or will be terminated on or prior
to the Closing Date and (d) the Permitted Surviving Debt (as defined below)). For purposes hereof, the term “Permitted
Surviving Debt” shall mean (1) purchase money indebtedness with respect to fixed assets, capital leases and equipment
financings of the Company or related to the Acquired Business, as applicable, existing on the date hereof, (2) purchase money indebtedness
with respect to inventory financings of the Company or related to the Acquired Business, as applicable, existing on the date hereof
and in an aggregate principal amount not to exceed $TBD, (3) unsecured intercompany indebtedness among the Company and its subsidiaries,
and (4) certain other indebtedness that the Company and the Lead Arrangers agree may remain outstanding after the Closing Date.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 5

 

		C.	Conditions Precedent.

 

The
undertakings, obligations, and commitments of SunTrust, Jefferies, and Morgan Stanley under this Commitment Letter are subject
to the satisfaction or waiver of solely the following conditions: (i) the Company’s compliance in all material respects with
the provisions of this Commitment Letter to be complied with by the Company, (ii) the satisfaction or waiver of each of the conditions
precedent set forth in the section entitled “Conditions to Closing and Initial Borrowing” in the Term Sheet, and (iii)
the Closing Date shall be (a) no earlier than the date that occurs 20 business days (or such earlier date as may be agreed to by
the Company and the Lead Arrangers) from the date on which the Company provides written authorization for the release of the CIM
(subject to the last sentence of this paragraph) and (b) no later than July 31, 2013. With respect to the preparation and
release of the CIM, the Lead Arrangers will deliver to the Company a final version of the CIM for its approval not later than three
(3) business days after the Company has provided to the Lead Arrangers all of the material information necessary to prepare the
CIM; provided that, if the Company reasonably believes that it has delivered such material information, Company may provide
written notice thereof to the Lead Arrangers stating when such delivery was made, in which case the Company shall be deemed to
have delivered such information and the 20 business day period shall begin to run on the third (3rd) business day thereafter
unless the Lead Arrangers reasonably believe that the Company has not completed delivery of such information and, within two (2)
business days after receipt of any such notice from the Company, provide written notice thereof to the Company stating with specificity
which information is required to complete the CIM.

 

Notwithstanding
anything in this Commitment Letter, the Fee Letters, the Financing Documentation or any other letter agreement, document, instrument,
agreement or other undertaking concerning the financing of the Transactions to the contrary, (i) the only representations and warranties
relating to the Company and its subsidiaries and businesses in the Financing Documentation the accuracy of which shall be a condition
to availability of the Senior Credit Facilities (other than the Delayed Draw Term Loan Facility) on the Closing Date shall be the
Specified Representations, (ii) the only representations and warranties relating to the Company, the Acquired Business, and their
respective subsidiaries and businesses in the Financing Documentation the accuracy of which shall be a condition to availability
of the Delayed Draw Term Loan Facility on the Delayed Draw Date shall be (a) the representations and warranties made by the Seller
in the Acquisition Agreement with respect to the Acquired Business as are material to the interests of the Lead Arrangers and the
Lenders, but only to the extent that the Company has the right to terminate its obligations under the Acquisition Agreement or
to otherwise elect not to consummate the Acquisition under the Acquisition Agreement as a result of a failure of such representations
and warranties to be accurate (the “Specified Acquisition Agreement Representations”) and (b) the Specified
Representations (as defined below), (iii) the terms of the Financing Documentation shall not impair availability of the Senior
Credit Facilities on the Closing Date if the conditions set forth in Section C of this Commitment Letter and the
section entitled “Conditions to Closing and Initial Borrowing” in the Term Sheet are satisfied or waived (it being
understood that (I) to the extent any security interest in the intended Collateral (other than any Collateral the security interest
in which may be perfected by (x) the filing of a UCC financing statement or (y) the delivery of stock certificates and related
stock powers, together with appropriate instruments of transfer, to the extent that such equity is certificated prior to the Closing
Date and is in the Company’s actual possession on the Closing Date) is not perfected on the Closing Date after the Company’s
use of commercially reasonable efforts to do so, the perfection of such security interest(s) will not constitute a condition precedent
to the availability of the Senior Credit Facilities on the Closing Date but such security interest(s) will be required to be perfected
after the Closing Date pursuant to arrangements to be mutually agreed by the Lead Arrangers and the Company and (II) nothing in
the preceding clause (I) shall be construed to limit the applicability of the individual conditions expressly listed in Section
C of this Commitment Letter and the section entitled “Conditions to Closing and Initial Borrowing” in the Term
Sheet), and (iv) the terms of the Financing Documentation shall not impair availability of the Delayed Draw Term Loan Facility
on the Delayed Draw Date if the conditions set forth in the section entitled “Conditions to Delayed Draw Term Loan”
in the Term Sheet are satisfied or waived (it being understood that (I) to the extent any security interest in the intended Collateral
(other than any Collateral the security interest in which may be perfected by (x) the filing of a UCC financing statement or (y)
the delivery of stock certificates and related stock powers, together with appropriate instruments of transfer, to the extent that
such equity is certificated prior to the Delayed Draw Date and is in the Company’s actual possession on the Delayed Draw
Date) is not perfected on the Delayed Draw Date after the Company’s use of commercially reasonable efforts to do so, the
perfection of such security interest(s) will not constitute a condition precedent to the availability of the Delayed Draw Term
Loan Facility on the Delayed Draw Date but such security interest(s) will be required to be perfected within 60 days after the
Delayed Draw Date and (II) nothing in the preceding clause (I) shall be construed to limit the applicability of the individual
conditions expressly listed in the section entitled “Conditions to Delayed Draw Term Loan” in the Term Sheet). As used
herein, “Specified Representations” means representations and warranties made by the Company and its
subsidiaries (including, with respect to the Specified Representations made on the Delayed Draw Date, after giving effect to the
Acquisition) in the Financing Documentation relating to incorporation or formation; organizational power and authority to enter
into the Financing Documentation; due execution, delivery and enforceability of the Financing Documentation; solvency; no conflicts
with laws, charter documents or material agreements (as such representations and warranties relate to the Financing Documentation
or, with respect to the Specified Representations made on the Delayed Draw Date, the Acquisition); compliance with laws, rules
and regulations (as such representations and warranties relate to the Financing Documentation or, with respect to the Specified
Representations made on the Delayed Draw Date, the Acquisition); Federal Reserve margin regulations; the Investment Company Act;
Patriot Act, OFAC, FCPA and anti-money laundering law compliance; and, subject to the limitations on perfection of security interests
set forth in the preceding sentence, the creation, perfection and priority of the security interests granted in the proposed collateral.
This paragraph is sometimes referred to as the “Certain Funds Provision”.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 6

 

		D.	Information Requirements

 

The Company represents
and warrants to the Lead Arrangers that (i) all written information, other than the Projections and other forward-looking information,
information regarding third parties and general economic or industry information, that has been or will be made available to any
of the Lead Arrangers or any of the Lenders by the Company or any of its representatives (or on its or their behalf) in connection
with the Senior Credit Facilities and the other Transactions (as modified or supplemented in writing by any other information so
furnished) (the “Information”) is or will be, when furnished and taken as a whole, complete and correct
in all material respects and does not or will not, when furnished and taken as a whole, contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements contained therein not materially misleading in
light of the circumstances under which such statements are made, and (ii) the Projections that have been or will be made available
to any of the Lead Arrangers or any of the Lenders by the Company or any of its representatives (or on its or their behalf) in
connection with the Senior Credit Facilities and the other Transactions have been or will be prepared in good faith based upon
assumptions believed to be reasonable at the time made; provided that it is expressly understood and agreed that financial projections
(including the Projections) are inherently uncertain and are not a guarantee of financial performance and that actual results may
differ from financial projections and such differences may be material. The Company agrees that, until the earlier of a Successful
Syndication and 60 days following the Closing Date, it will (a) provide prompt written notice to the Lead Arrangers if the representations
and warranties contained in the preceding sentence become incorrect at any time and for any reason and (b) promptly supplement
the Information or the Projections, as the case may be, from time to time so that the representations and warranties contained
in the first sentence of this paragraph are correct. In issuing the commitments and undertakings under this Commitment Letter and
in arranging and syndicating the Senior Credit Facilities, SunTrust, Jefferies, and Morgan Stanley are relying on the Information
and the Projections without independent verification.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 7

 

The Company authorizes
the Lead Arrangers and their respective affiliates to share with each other, and to use, credit and other confidential or non-public
information regarding the Company, the Acquired Business, and the Seller to the extent permitted by applicable laws and regulations
and for the purpose of performing their obligations under this Commitment Letter and the Senior Credit Facilities; provided
that, to the extent that any such information is made available to prospective Lenders, such parties shall have agreed to be bound
by customary confidentiality undertakings (including “click-through” agreements), all in accordance with the Lead Arrangers’
standard loan syndication practices (whether transmitted electronically by means of a website, e-mail or otherwise, or made available
orally or in writing, including at prospective Lender or other meetings).

 

		E.	Fees;
                                                                                                                                                                             Indemnification;
                                                                                                                                                                             Expenses.

 

1.         Fees; Expenses. In addition
to, but without duplication of, the fees described in the Term Sheet, the Company will pay (or cause to be paid) the fees set forth
in, and in accordance with, (a) that certain letter agreement dated as of the date hereof, executed by SunTrust Bank, STRH, Jefferies,
and Morgan Stanley and acknowledged and agreed to by the Company relating to this Commitment Letter (the “Lead Arranger
Fee Letter”) and (b) that certain letter agreement dated as of the date hereof, executed by SunTrust Bank and STRH
and acknowledged and agreed to by the Company relating to this Commitment Letter (the “Agency Fee Letter”
and, together with the Lead Arranger Fee Letter, collectively, the “Fee Letters”). The Company also agrees
to pay, or to reimburse SunTrust, Jefferies, and Morgan Stanley on demand for, all reasonable and documented costs and expenses
(whether incurred before or after the date hereof) incurred in connection with the Senior Credit Facilities, the due diligence
relating thereto, the syndication thereof, and the preparation of the Financing Documentation, including, without limitation, with
respect to SunTrust only, the reasonable and documented fees, disbursements, and expenses of one outside counsel (and any required
special or local counsel), in each case, regardless of whether the Senior Credit Facilities close. The Company also agrees to pay
all documented costs and expenses of each of SunTrust, Jefferies, and Morgan Stanley (including, without limitation, documented
fees and disbursements one outside counsel to each such party (and any required special or local counsel to each such party)) incurred
in connection with the enforcement of any of its rights and remedies under this Commitment Letter or any Fee Letter.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 8

 

2.         Indemnification.  The
Company agrees to indemnify and hold harmless the Lead Arrangers, SunTrust Bank, each other Lender, their respective affiliates
and their respective directors, officers, employees, agents, representatives, legal counsel, and consultants (each, an “Indemnified
Person”) against, and to reimburse each Indemnified Person upon demand for, any losses, claims, damages, liabilities
or other expenses (“Losses”) incurred by such Indemnified Person or asserted against such Indemnified
Person by any third party or by the Company or any of its subsidiaries or affiliates arising out of or in connection with this
Commitment Letter, the Fee Letters, the Senior Credit Facilities, the use of the proceeds of the Senior Credit Facilities or any
other Transaction, or any suit, claim, litigation, investigation or proceeding brought by the Company or the Company’s equity
holders, affiliates or creditors or any third person or otherwise relating to any of the foregoing, and to reimburse each Indemnified
Person upon demand for any legal or other expenses incurred in connection with investigating or defending any of the foregoing,
whether or not such Indemnified Person or the Company is a party to any such proceeding; provided that the Company shall
not be liable to an Indemnified Person pursuant to this indemnity for any Losses or any other amounts to the extent that a court
having competent jurisdiction shall have determined by a final judgment (not subject to further appeal) that such Loss or other
amount resulted from (a) the bad faith, gross negligence or willful misconduct of such Indemnified Person or (b) a material breach
by such Indemnified Person of any of its undertakings, obligations or commitments under this Commitment Letter, the Fee Letters,
the Senior Credit Facilities or the use of the proceeds of the Senior Credit Facilities. No Indemnified Person shall be responsible
or liable for any damages arising from the use by others of the Information or other materials obtained through electronic, telecommunications
or other information transmission systems, except to the extent a court having competent jurisdiction shall have determined by
a final judgment (not subject to further appeal) that such liability resulted from the bad faith, gross negligence or willful misconduct
of such Indemnified Person, or for any special, indirect, punitive, exemplary or consequential damages that may be alleged as a
result of this Commitment Letter, the Fee Letters, the Senior Credit Facilities, the use of proceeds of the Senior Credit Facilities
or any other Transaction.

 

		F.	Special Disclosure

 

STRH is a wholly-owned
subsidiary of SunTrust Banks, Inc. (“STBI”) and an affiliate of SunTrust Bank. STRH is a broker/dealer
registered with the Securities and Exchange Commission and a member of the National Association of Securities Dealers, Inc. and
the Securities Investor Protection Corporation (“SIPC”). Although it is a subsidiary of STBI, STRH is
not a bank and is separate from SunTrust Bank or any banking affiliate of SunTrust Bank. STRH is solely responsible for its contractual
obligations and commitments. Securities and financial instruments sold, offered, or recommended by STRH are not bank deposits,
are not insured by the Federal Deposit Insurance Corporation, SIPC or any governmental agency and are not obligations of or endorsed
or guaranteed in any way by any bank affiliated with STRH or any other bank unless otherwise stated.

 

		G.	Miscellaneous

 

1.         Termination.
This Commitment Letter and all commitments and undertakings of the Lead Arrangers, SunTrust, Jefferies, and Morgan Stanley under
this Commitment Letter shall expire at 5:00 p.m., Atlanta, Georgia time, on June 17, 2013, unless by such time the Company
both executes and delivers to the Lead Arrangers this Commitment Letter and the Fee Letters. Thereafter, all commitments and obligations
of the Lead Arrangers, SunTrust, Jefferies, and Morgan Stanley under this Commitment Letter will terminate on the earliest of (i)
5:00 p.m., Atlanta, Georgia time on July 31, 2013, unless the Financing Documentation related to the Senior Credit Facilities has
been executed and delivered on or prior to such date (in which case, such commitments shall be subject to the terms set forth in
the Financing Documentation) and (ii) the date on which the parties hereto mutually agree to terminate this Commitment Letter.

 

2.         No Third-Party
Beneficiaries. This Commitment Letter is solely for the benefit of the Company, SunTrust, Jefferies, Morgan Stanley, and the
Indemnified Persons; no provision of this Commitment Letter shall be deemed to confer rights on any other person or entity.

 

3.         No Assignment;
Amendment. This Commitment Letter and the Fee Letters may not be assigned by the Company to any other person or entity, but
all of the obligations of the Company under this Commitment Letter and under the Fee Letters shall be binding upon the successors
and assigns of the Company. This Commitment Letter and the Fee Letters may not be amended or modified except in writing executed
by each of the parties hereto.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 9

 

4.         Use of Name and Information.
The Company agrees that any references to any Lead Arranger or any of their respective affiliates made in connection with the Senior
Credit Facilities are subject to the prior approval of such Lead Arranger, which approval shall not be unreasonably withheld. Each
Lead Arranger shall be permitted to use information related to the Company, the Acquired Business, and the Seller in connection
with the syndication and arrangement of the Senior Credit Facilities pursuant to this Commitment Letter. Further, each of the Lead
Arrangers shall be permitted at any time to use information related to the Company, the Acquired Business, and the Seller without
the Company’s, the Acquired Business’, or the Seller’s prior approval with respect to marketing, press releases
or other transactional announcements or updates provided to investor or trade publications, including, but not limited to, the
placement of “tombstone” advertisements in publications of its choice at its own expense so long as the information
is limited to the name of any Credit Party (including, without limitation, the Company and the Acquired Business) or any Lender
and the amount of the Senior Credit Facilities, type of Senior Credit Facilities, the actual or anticipated closing date thereof
and the actual or anticipated maturity date of the Senior Credit Facilities, and, after the closing date thereof, the pricing of
the Senior Credit Facilities. Each of the Lead Arrangers agrees that its use of any other information related to the Company not
identified in this Section G.4. is subject to the prior approval of the Company, which approval shall not be unreasonably
withheld.

 

5.         Governing Law. This Commitment
Letter and the Fee Letters will be governed by and construed in accordance with the laws of the state of New York. Each of the
Company, SunTrust, Jefferies, and Morgan Stanley irrevocably waives all right to trial by jury in any action, proceeding or counterclaim
(whether based on contract, tort or otherwise) arising out of or related to this Commitment Letter, the Fee Letters, the Senior
Credit Facilities, the use of proceeds of the Senior Credit Facilities or the actions of SunTrust, Jefferies, or Morgan Stanley
in the negotiation, performance or enforcement of this Commitment Letter. The Company irrevocably and unconditionally submits to
the exclusive jurisdiction of any state court in the State of New York or the United States District Court for the Southern District
of New York for the purpose of any suit, action or proceeding arising out of or relating to this Commitment Letter, the Fee Letters,
the Senior Credit Facilities and the use of proceeds of the Senior Credit Facilities and irrevocably agrees that all claims in
respect of any such suit, action or proceeding may be heard and determined in any such court. Each of the Company, SunTrust, Jefferies,
and Morgan Stanley irrevocably and unconditionally waives any objection that it may now or hereafter have to the laying of venue
of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding has been
brought in an inconvenient forum. A final judgment in any such suit, action or proceeding brought in any such court may be enforced
in any other courts to whose jurisdiction the Company, SunTrust, Jefferies, or Morgan Stanley are or may be subject, by suit upon
judgment. Service of any process, summons, notice or document on the Company may be made by registered mail addressed to the Company
at the address appearing at the beginning of this letter for any suit, action or proceeding brought in any such court pursuant
to this Commitment Letter.

 

6.         Survival. The obligations
of the Company under the expense reimbursement, indemnification, confidentiality, governing law, and waiver of certain defenses
provisions of this Commitment Letter shall survive the expiration and termination of this Commitment Letter and the execution and
delivery of the Financing Documentation. Not in limitation of the foregoing, the obligations of the Company under Section B and
Section D of this Commitment Letter with respect to the syndication of the Senior Credit Facilities shall survive the execution
and delivery of the Financing Documentation.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 10

 

7.         Confidentiality. The Company
will not disclose or permit disclosure of this Commitment Letter, the Fee Letters or the contents of the foregoing to any person
or entity (including, without limitation, any Lender other than SunTrust, Jefferies, or Morgan Stanley), either directly or indirectly,
orally or in writing, except (i) to the Company’s officers, directors, agents, employees, advisors, consultants, equityholders,
members, managers and legal counsel, in each case, on a confidential basis, (ii) as required by law or regulation (in which case
the Company agrees to inform the Lead Arrangers promptly thereof to the extent legally permitted to do so), (iii) with the written
consent of the Lead Arrangers, and (iv) the Commitment Letter and a redacted version of the Lead Arranger Fee Letter (which redacted
version may include market flex terms but shall exclude specific pricing and fee information) may be disclosed to the Seller and
its officers, directors, agents, employees, advisors, consultants, equityholders, members, managers and legal counsel, in each
case, on a confidential basis and only in connection with the Acquisition.

 

8.         No Fiduciary Duty. The
Company acknowledges and agrees that (i) the commitment to and syndication of the Senior Credit Facilities pursuant to this Commitment
Letter represent an arm's-length commercial transaction between the Company, on the one hand, and SunTrust, Jefferies, and Morgan
Stanley on the other; (ii) the Company is capable of evaluating and understanding, and does understand and accept, the terms, risks
and conditions of the transactions contemplated by this Commitment Letter; (iii) in connection with the transactions contemplated
by this Commitment Letter and the process leading to such transactions, each of SunTrust, Jefferies, and Morgan Stanley is and
has been acting solely as a principal and is not the agent or fiduciary of the Company or its affiliates, stockholders, creditors,
employees or any other party; (iv) none of SunTrust, Jefferies, or Morgan Stanley has assumed an advisory responsibility or fiduciary
duty in favor of the Company with respect to the transactions contemplated by this Commitment Letter or the process leading to
this Commitment Letter (irrespective of whether SunTrust, Jefferies, or Morgan Stanley has advised or is currently advising the
Company on other matters), and none of SunTrust, Jefferies, or Morgan Stanley has any obligation to the Company with respect to
the Senior Credit Facilities except those expressly set forth in this Commitment Letter; (v) SunTrust, Jefferies, Morgan Stanley,
and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
the Company and its affiliates, and none of SunTrust, Jefferies, or Morgan Stanley has any obligation to disclose any of such interests
by virtue of any fiduciary or advisory relationship as a consequence of this Commitment Letter; and (vi) none of SunTrust, Jefferies,
or Morgan Stanley has provided any legal, accounting, regulatory or tax advice to the Company with respect to any of the transactions
contemplated by this Commitment Letter, and the Company has consulted its own legal, accounting, regulatory and tax advisors to
the extent it deemed appropriate. The Company waives and releases, to the fullest extent permitted by law, any claims that it may
have against SunTrust, Jefferies, and/or Morgan Stanley with respect to any breach or alleged breach of fiduciary duty as a consequence
of this Commitment Letter.

 

9.         Affiliates. The Lead Arrangers reserve the right
to employ the services of their affiliates or branches in providing services contemplated hereby and to allocate, in whole or in
part, to their affiliates or branches certain fees payable to the Lead Arrangers hereunder or under the Lead Arranger Fee Letter
in such manner as the Lead Arrangers and their affiliates or branches may agree in their sole discretion (so long as such allocation
does not result in an increase in the aggregate amount of fees payable by the Company in accordance with the Lead Arranger Fee
Letter) and, to the extent so employed, such affiliates and branches shall be entitled to the benefits and protections afforded
to, and subject to the provisions governing the conduct of the Lead Arrangers hereunder and under the Lead Arranger Fee Letter.

  

10.         Counterparts.
This Commitment Letter and the Fee Letters may be executed in multiple counterparts, and by different parties in any number of
separate counterparts, all of which taken together shall constitute one original. Delivery of an executed counterpart of a signature
page to this Commitment Letter or the Fee Letters by telecopier or by electronic transmission (in pdf form) shall be as effective
as delivery of a manually executed counterpart of this Commitment Letter.

 

    	 

    	 

    

 

BioScrip, Inc.

June 16, 2013

Page 11

 

11.         Entire Agreement.
This Commitment Letter and the Fee Letters embody the entire agreement and understanding among SunTrust, Jefferies, Morgan Stanley,
the Company, and their affiliates with respect to the Senior Credit Facilities and supersede all prior understandings and agreements
among the parties relating to the Senior Credit Facilities. However, the terms and conditions of the commitments of SunTrust Bank,
Jefferies, and Morgan Stanley and the undertaking of the Lead Arrangers under this Commitment Letter are not limited to those set
forth in this Commitment Letter, in the Term Sheet or in the Fee Letters; those matters not covered or made clear in this Commitment
Letter or in the Term Sheet are subject to mutual agreement of the parties.

 

12.         Patriot Act.
Each of SunTrust, Jefferies, and Morgan Stanley hereby notifies the Company and the Guarantors that pursuant to the requirements
of the USA Patriot Act, Title III of Pub. L. 107-56 (signed into law October 26, 2001) (the “Patriot Act”),
it and its affiliates are required to obtain, verify and record information that identifies the Company and the Guarantors, which
information includes the names, addresses, tax identification numbers and other information regarding the Company and the Guarantors
that will allow SunTrust, Jefferies, and Morgan Stanley to identify the Company and the Guarantors in accordance with the Patriot
Act. This notice is given in accordance with the requirements of the Patriot Act and is effective for SunTrust, Jefferies, Morgan
Stanley, and their respective affiliates.

 

13.         Consultation
with Company. The Company hereby acknowledges and agrees that any consultation right of the Company set forth in this Commitment
Letter, the Term Sheet, or the Fee Letters does not imply a veto right or consent right.

 

[Remainder of page intentionally blank;
signature page follows]

 

    	 

    	 

    

 

We look forward to
working with you on this important transaction.

 

	 	Very truly yours,
	 	 	 
	 	SUNTRUST BANK
	 	 	 
	 	By:	/s/ J. Ben Cumming
	 	 	Name: J. Ben Cumming
	 	 	Title: Director

 

	 	SUNTRUST ROBINSON HUMPHREY, INC.
	 	 	 
	 	By:	/s/ Patrick M. Stevens
	 	 	Name: Patrick M. Stevens
	 	 	Title: Managing Director

 

[BIOSCRIP –COMMITMENT LETTER]

 

    	 

    	 

    

 

	 	JEFFERIES FINANCE LLC
	 	 	 
	 	By:	/s/ Brian Buoye
	 	 	Name: Brian Buoye
	 	 	Title: Managing Director

 

[BIOSCRIP –COMMITMENT LETTER]

 

    	 

    	 

    

 

	 	MORGAN STANLEY SENIOR FUNDING, INC.
	 	 	 
	 	By:	/s/ Nathan Speicher
	 	 	Name: Nathan Speicher
	 	 	Title: Authorized Signatory

 

[BIOSCRIP –COMMITMENT LETTER]

 

    	 

    	 

    

 

ACCEPTED AND AGREED

this 14 day of June, 2013:

 

	BIOSCRIP, INC.	 
	 	 	 
	By:	/s/ Hai Tran	 
	Name: Hai Tran	 
	Title: CFO	 

 

[BIOSCRIP –COMMITMENT LETTER] 

 

    	 

    	 

    

 

EXHIBIT A

 

Summary of Principal Terms
and Conditions of 

$475,000,000 Senior Secured
Credit Facilities

 

Capitalized terms not otherwise defined
in this Summary of Principal Term and Conditions (this “Term Sheet”) have the meanings set forth in the Commitment
Letter to which this Term Sheet is attached (together with this Term Sheet, the “Commitment Letter”).

 

	Borrower:	 	BioScrip, Inc., a Delaware
    corporation (the “Borrower”).
	 	 	 
	Guarantors:	 	The Senior Credit Facilities (as defined
    below) and, to the extent provided by the Administrative Agent, any Lender or any of their respective affiliates, all monetary
    liabilities arising from cash management services, treasury management services (including, without limitation, credit cards,
    purchasing cards and debit cards), and interest rate protection and other hedging arrangements owed to the Administrative
    Agent, any such Lender or any such affiliate (other than, with respect to any Guarantor, any hedging obligation that cannot
    be guaranteed by such Guarantor by virtue of such Guarantor not constituting an “eligible contract participant”
    under the Commodity Exchange Act) will be guaranteed by all existing and future direct and indirect domestic subsidiaries
    of the Borrower (collectively, the “Guarantors” and, together with the Borrower, the “Credit
    Parties”).
	 	 	 
	Joint Lead Arrangers and Joint Bookrunners:	 	SunTrust Robinson Humphrey, Inc. (“STRH”),
    Jefferies Finance LLC (“Jefferies”), and Morgan Stanley Senior Funding, Inc. (“Morgan
    Stanley” and, together with STRH and Jefferies, collectively, the “Lead Arrangers”).
	 	 	 
	Syndication Agent:	 	Jefferies Finance LLC
	 	 	 
	Documentation Agent:	 	Morgan Stanley Senior Funding, Inc.
	 	 	 
	Administrative Agent:	 	SunTrust Bank (“Administrative
    Agent”).
	 	 	 
	Lenders:	 	A syndicate of financial institutions
    arranged and approved by STRH in consultation with the Borrower and the Administrative Agent (collectively, the “Lenders”).
	 	 	 
	Senior Credit Facilities:	 	Senior credit facilities in an aggregate
    principal amount of $475,000,000 comprised of the following:
	 	 	 
	 	 	Revolving Credit Facility:  A
    $75,000,000 revolving credit facility (the “Revolver”), including a $20,000,000 sublimit for the
    issuance of standby letters of credit (each a “Letter of Credit”), and a $10,000,000 sublimit for
    swingline loans (each a “Swingline Loan”).  Letters of Credit will be issued by SunTrust
    Bank (the “Issuing Bank”) and Swingline Loans (the “Swingline Lender”)
    will be made available by SunTrust Bank in its sole discretion, and each Lender with a commitment under the Revolver will
    purchase an irrevocable and unconditional participation in each Letter of Credit and each Swingline Loan. 

 

    	1

    	 

    

 

BioScrip, Inc.

 

	 	 	Term B Loan:  A
    $250,000,000 term loan B advanced in one drawing on the Closing Date (the “Initial Term B Loan”).
	 	 	 
	 	 	Delayed Draw Term Loan:  A
    $150,000,000 senior secured delayed draw term loan B (the “Delayed Draw Term Loan”) will be advanced
    in one drawing on the date on which the Acquisition (as defined below) is consummated (the “Delayed Draw Date”),
    which shall in no event be later than October 31, 2013.  Any portion of the Delayed Draw Term Loan that has not
    been funded on or prior to October 31, 2013, shall be permanently cancelled.
	 	 	 
	 	 	Loans and extensions of credit will
    be made only in U.S. dollars.  
	 	 	 
	 	 	The Initial Term B Loan, the Delayed
    Draw Term Loan, and any Incremental Term Loan are collectively referred to in this Term Sheet as the “Term B Loans.”  The
    Revolver and the Term B Loans are collectively referred to in this Term Sheet as the “Senior Credit
    Facilities.”  The date on which the Senior Credit Facilities (other than the Delayed Draw Term Loan)
    are initially funded is referred to in this Term Sheet as the “Closing Date.”  
	 	 	 
	Purpose:	 	The proceeds of the Revolver and the
    Initial Term B Loan shall be used only to (i) refinance certain existing indebtedness of the Credit Parties (other than Permitted
    Surviving Debt) (the “Refinancing”), (ii) fund other Permitted Acquisitions (as defined below) and
    pay fees and expenses incurred in connection therewith, (iii) finance capital expenditures and working capital needs of the
    Credit Parties, (iv) fund other general corporate purposes of the Borrower and its subsidiaries, (v) pay fees and expenses
    incurred in connection with the Senior Credit Facilities and the Refinancing, and (vi) with respect to the Revolver, for the
    purposes set forth in the immediately following paragraph.  No loans under the Revolver shall be outstanding on
    the Closing Date, other than (x) to issue Letters of Credit to replace, backstop or provide other credit support for any existing
    letters of credit and to issue Letters of Credit in connection
    with “grandfathering” existing letters of credit into the Revolver so long as the issuer of each such existing
    letter of credit is a Lender under the Senior Credit Facilities and (y) to fund original issue discount resulting from the
    exercise of the Market Flex provisions in the Lead Arranger Fee Letter or additional fees payable under the Fee Letters.
	 	 	 
	 	 	The proceeds of the Delayed Draw Term
    Loan shall be used only to, and so long as the Delayed Draw Term Loan is fully funded, the proceeds of the Revolver may be
    used to, (i) fund a portion of the consideration paid by the Borrower for the acquisition (the “Acquisition”)
    of substantially all of the assets of a company previously identified to us as “Cassidy” (the “Acquired
    Business”) from CarePoint Partners Holdings LLC, a Delaware limited liability company (“CarePoint”),
    and the direct and indirect subsidiaries of CarePoint set forth on the signature pages to the Acquisition Agreement (CarePoint
    and such subsidiaries, collectively, “Seller”) and repay certain existing indebtedness of the Acquired
    Business (other than Permitted Surviving Debt) (the “Acquired Business Refinancing”) and (ii) pay
    fees and expenses incurred in connection with the consummation of the Acquisition. 

 

    	2

    	 

    

 

BioScrip, Inc.

 

	 	 	As used herein, the term
    “Transactions” means the Acquisition, the Acquired Business Refinancing, the Refinancing, the entering
    into of the Commitment Letter and the Fee Letters delivered in connection herewith, the entering into of the Senior Credit
    Facilities and the initial borrowings thereunder, and the payment of fees and expenses in connection with each of the foregoing.  
	 	 	 
	Amortization and Maturity Date:	 	The Revolver shall terminate, and all
    amounts outstanding under it shall be due and payable in full, on the fifth anniversary of the Closing Date. 
	 	 	 
	 	 	The Initial Term B Loan will amortize
    in equal quarterly principal installments in an aggregate annual amount equal to 1.0% per annum of the original principal
    amount of the Initial Term B Loan, commencing on the last day of the first full calendar quarter beginning after the Closing
    Date, with the remaining outstanding principal balance of the Initial Term B Loan to be due and payable in full on seventh
    anniversary of the Closing Date.
	 	 	 
	 	 	To the extent funded, the Delayed Draw
    Term Loan will have the same amortization schedule (commencing on the last day of the first full calendar quarter beginning
    after the Delayed Draw Date) and maturity date as the Initial Term B Loan. 
	 	 	 
	 	 	Subject to terms and conditions to
    be mutually agreed, the loan documentation evidencing the Senior Credit Facilities (the “Financing Documentation”)
    shall provide the right of individual Lenders to agree to extend the maturity of their respective Revolver commitments or
    their respective portions of the Term B Loans (which extensions may include increases in pricing) upon the request of the
    Borrower and without the consent of any other Lender.
	 	 	 
	Pricing/Fees/Expenses:	 	As set forth in the Fee Letters and
    Addendum I attached to this Term Sheet.
	 	 	 
	Optional Prepayments and Revolver Reductions:	 	Subject to section titled “Prepayment
    Premium” below, prepayments may be made, in whole or in part, without premium or penalty, subject to reimbursement of
    the Lenders’ breakage and redeployment costs in the case of prepayment of LIBOR borrowings.  Prepayments of
    the Term B Loans may at the Borrower’s option be applied to amortization payments scheduled to occur in the succeeding
    12 calendar months following such prepayment in direct order and, thereafter, on a pro rata basis to the remaining amortization
    payments.  Any unutilized portion of the Revolver commitment and the Delayed Draw Term Loan commitment may be irrevocably
    reduced or terminated by the Borrower at any time without penalty.

 

    	3

    	 

    

 

BioScrip, Inc.

 

	Mandatory Prepayments:	 	The Borrower shall be required
    to prepay the Senior Credit Facilities with (i) 100% of the net cash proceeds from the sale or disposition of assets (other
    than sales of inventory in the ordinary course of business, dispositions of worn out and obsolete equipment otherwise not
    prohibited by the Financing Documentation, dispositions of assets to other Credit Parties, dispositions of immaterial subsidiaries
    and immaterial investments, and other customary exceptions to be mutually agreed) and insurance and condemnation proceeds
    in excess of $10,000,000 in the aggregate during any fiscal year (subject to a 365/366 day period to reinvest or commit
    to reinvest (subject to an additional 180 day period for any such commitment to be reinvested) such proceeds in the business
    of the Borrower and no event of default existing at the time of receipt of such proceeds), (ii) 100% of net cash proceeds
    from the issuance of any debt by the Borrower or any of its subsidiaries (other than debt not prohibited to be issued under
    the terms of the Financing Documentation), and (iii) commencing with the fiscal year ending December 31, 2014, 50% of excess
    cash flow (to be defined on customary and reasonable terms and including deductions for, among others, (a) cash purchase consideration,
    as well as related costs and expenses, of Permitted Acquisitions, (b) permitted capital expenditures, (c) permitted investments,
    (d) permitted distributions and other permitted restricted payments (including permitted cash dividends), and (e) all other
    cash items added back in the calculation of “Consolidated EBITDA”, in each case, made during such period) of the
    Borrower and its subsidiaries, for such fiscal year if on the last day of the fiscal year for which such payment is being
    made the Total Net Leverage Ratio (as defined below) equals or exceeds 3.50 to 1.00 (at all other times there shall be no
    mandatory prepayment with any portion of the Borrower’s excess cash flow).  Voluntary prepayments of the Term
    B Loans and advances funded under the Revolver (to the extent accompanied by permanent commitment reductions) shall be credited
    dollar-for-dollar against required excess cash flow prepayments.  All such prepayments shall be applied to the Senior
    Credit Facilities first, pro rata to the Term B Loans (and to the principal installments thereof on a pro rata basis) until
    paid in full and then to the Revolver (without permanent reduction of the commitments thereunder). 
	 	 	 
	 	 	For purposes of this Term Sheet, the
    term “Total Net Leverage Ratio” shall mean, as of any date, the ratio of (i) the sum of total consolidated
    funded debt1 (less unrestricted cash and cash
    equivalents (for the avoidance of doubt, excluding proceeds of any loans being made on the date that the Total Net Leverage
    Ratio is tested)) on such date to (ii) Consolidated EBITDA for the four consecutive fiscal quarters ending on such date.

 

 

 1
Consolidated funded debt to exclude any obligations owed by the Credit Parties to AmerisourceBergen Drug Corporation under
the Prime Vendor Agreement.

 

    	4

    	 

    

 

BioScrip, Inc.

 

	Prepayment Premium:	 	If, within six months
    after the Closing Date, the Term B Loans are refinanced with the proceeds of indebtedness having a lower applicable margin
    or yield than that applicable to the Term B Loans, then the prepayment of the Term B Loans in connection with such refinancing
    shall be made at 101% of the principal amount so prepaid.  Downward repricings of the Term B Loans within six months
    after the Closing Date through an amendment to the Financing Documentation will be deemed a refinancing for purposes of this
    paragraph.
	 	 	 
	Collateral:	 	The Senior Credit Facilities and, to
    the extent provided by the Administrative Agent, any Lender or any of their respective affiliates, all monetary liabilities
    arising from cash management services, treasury management services (including, without limitation, credit cards, purchasing
    cards and debit cards), interest rate protection and other hedging arrangements owed to the Administrative Agent, any such
    Lender or any such affiliate (other than, with respect to any Guarantor, any hedging obligation that cannot be guaranteed
    by such Guarantor by virtue of such Guarantor not constituting an “eligible contract participant” under the Commodity
    Exchange Act) shall be secured on a pari passu basis by a first priority security interest (subject to Specified Permitted
    Liens (as defined below)) in and lien on all personal property and material owned real property of the Borrower and Guarantors
    and a pledge of 100% of each Credit Party’s equity (other than the Borrower’s equity), including without limitation,
    all accounts, deposit accounts (subject to customary account control agreements and, with respect to deposit accounts into
    which government receivables and reimbursement payments are deposited, customary government receivables account control agreements),
    inventory, equipment, general intangibles, goods, documents, contracts, trademarks, patents, copyrights, intercompany obligations,
    stock, securities, notes, and material real estate owned by Borrower or any Guarantor (the “Collateral”),
    other than any Excluded Assets (as defined below).  Notwithstanding the foregoing, in respect of any stock of any
    foreign subsidiaries of any Credit Party, such pledge shall be limited to 65% of the voting capital stock of such Credit Party’s
    first tier foreign subsidiaries.  With respect to the leased property of the Borrower and the Guarantors located
    at 10050 Crosstown Circle, Suite 300, Eden Prairie, Minnesota 55344 and 100 Clearbrook Road, Elmsford, New York 10523 and
    all other material leased real property of the Borrower and Guarantors, the Borrower and Guarantors shall be required to use
    commercially reasonable efforts within a reasonable period of time following the Closing Date to obtain customary agreements
    with landlords in form and substance reasonably satisfactory to the Administrative Agent.

 

    	5

    	 

    

 

BioScrip, Inc.

 

	 	 	Notwithstanding anything
    to the contrary, the Collateral shall exclude the following (the “Excluded Assets”): (i) any fee-owned
    real property with a fair market value of less than $5,000,000 and all leasehold interests; (ii) motor vehicles and other
    assets subject to certificates of title to the extent that a security interest therein cannot be perfected by the filing of
    a UCC-1 financing statement; (iii) letter of credit rights (except to the extent constituting a support obligation for other
    Collateral as to which the perfection of security interests in such other Collateral and the support obligation is accomplished
    solely by the filing of a UCC-1 financing statement) and commercial tort claims, in each case, with a value of less than an
    amount to be agreed; (iv) equity interests of non-wholly owned subsidiaries and joint ventures, to the extent a pledge thereof
    is not permitted by the organizational documents of such non-wholly owned subsidiaries and joint ventures; (v) licenses, instruments,
    agreements and other general intangibles (other than proceeds and receivables thereof) to the extent, and so long as, the
    pledge thereof as Collateral would violate the terms thereof or result in a breach by any Credit Party of any agreement related
    thereto but only to the extent, and for so long as, such prohibition is not terminated or rendered unenforceable or otherwise
    deemed ineffective by the Uniform Commercial Code (“UCC”), Title 11 of the United States Code (the
    “Bankruptcy Code”) or any other requirement of law and such prohibition is not prohibited under
    the negative covenant governing negative pledge clauses and restrictions on distributions, advances and asset transfers by
    subsidiaries; (vi) zero balance accounts, payroll accounts, withholding and trust accounts, tax accounts, escrow or other
    fiduciary accounts, local or petty cash accounts containing less than a to-be-determined amount and accounts into which government
    receivables and government reimbursement payments are deposited (provided, however, that such accounts shall be subject to
    customary government receivables account control agreements); (vii) other assets to the extent the pledge thereof is prohibited
    by applicable law (other than proceeds and receivables thereof), but only to the extent, and for so long as, such prohibition
    is not terminated or rendered unenforceable or otherwise deemed ineffective by the UCC, Bankruptcy Code or any other requirement
    of law; (viii) those assets as to which the Administrative Agent shall reasonably determine that the costs of obtaining or
    perfecting such security interest are excessive in relation to the value of the security to be afforded thereby; and (ix)
    such other assets of the Borrower and the Guarantors as may be reasonably agreed by the Administrative Agent.
	 	 	 
	 	 	The liens securing the Senior Credit
    Facilities will be senior to the liens granted by the Credit Parties to AmerisourceBergen Drug Corporation.
	 	 	 
	 	 	For purposes of this Term Sheet, the
    term “Specified Permitted Liens” shall mean (a) nonconsensual liens arising by operation of law,
    (b) purchase money liens on fixed assets and liens on fixed assets securing capital leases so long as (i) such lien granted
    is limited to the specific fixed assets acquired and the proceeds thereof and (ii) the aggregate principal amount of indebtedness
    secured by such lien is not more than the acquisition cost of the specific fixed assets on which the lien is granted, (c)
    purchase money liens on inventory in an aggregate amount not to exceed $TBD so long as (i) such lien granted is limited to
    the specific inventory acquired and (ii) the aggregate principal amount of indebtedness secured by such lien is not more than
    the acquisition cost of the inventory on which the lien is granted, and (d) other liens consented to in writing by the Lead
    Arrangers.  

 

    	6

    	 

    

 

 

BioScrip, Inc.

 

	Incremental Facility:	 	The Borrower
    shall have the right to increase the existing commitments under the Revolver (each such increase, an “Incremental
    Revolving Facility”) and/or obtain new term B loans (each new term B loan, an “Incremental Term
    Loan” and, together with any Incremental Revolving Facility, an “Incremental Facility”)
    at any time and from time to time on or before the maturity date of the relevant Senior Credit Facility in the aggregate amount
    of (x) $100,000,000 plus (y) an unlimited additional incremental amount so long as, with respect to such additional
    incremental amount under this clause (y) only, the Total Net Leverage Ratio on a pro forma basis after giving effect to any
    such additional incremental amount (and the anticipated use of proceeds thereof, assuming, in the case of any Incremental
    Revolving Facility, a full utilization thereof) is less than or equal to 4.50 to 1.00; provided, that (i) any new lenders
    under an Incremental Revolving Facility are approved by the Administrative Agent in its sole discretion, (ii) no commitment
    of any Lender shall be increased without the consent of such Lender, (iii) all conditions to borrowings after the Closing
    Date (other than conditions to the borrowing of the Delayed Draw Term Loan) set forth in the Financing Documentation are satisfied
    or waived, (iv) no event of default under the Financing Documentation shall exist, (v) the final maturity date and the weighted
    average life to maturity of any Incremental Term Loan shall be no earlier than the final stated maturity date and no shorter
    than the weighted average life to maturity of any existing Term B Loan, respectively, (vi) any Incremental Revolving Facility
    shall become part of the Revolver and shall have the same terms and conditions as the Revolver, including, without limitation,
    the same maturity date and interest rates (subject to the last sentence of this section), and (vii) all obligations under
    all Incremental Facilities (assuming, in the case of any Incremental Revolving Facility, a full utilization thereof) shall
    constitute “senior obligations” under all intercreditor agreements entered into with respect to the Senior Credit
    Facilities, including, without limitation, the ABDC Intercreditor Agreement.  Each Incremental Facility shall become
    part of the Senior Credit Facilities, subject to the terms for such Incremental Facility.  To the extent that the
    all-in pricing (including interest rates and upfront fees (equated to an increase in interest rates (based on an assumed 4-year
    average life to maturity or the remaining life to maturity)), but excluding any arrangement fee, structuring fee, underwriting
    fee and other fees paid in connection with the arrangement of any Incremental Facility) for any Incremental Facility is more
    than 50 basis points higher than the pricing of the corresponding Senior Credit Facility, the pricing (including interest
    rates and upfront fees but excluding any arrangement fee, structuring fee, underwriting fee and other fees paid in connection
    with the arrangement of such Incremental Facility) on the applicable Senior Credit Facility shall be increased to an amount
    equal to the all-in pricing on such Incremental Facility minus 50 basis points.
	 	 	
	Conditions to Closing and
    Initial Borrowing:	   	The availability of the Senior Credit
    Facilities on the Closing Date will be subject to the Certain Funds Provision in all respects and the satisfaction or waiver
    of solely the conditions set forth in Section C of the Commitment Letter and the following conditions:

 

    	7

    	 

    

 

BioScrip, Inc.

 

	 	 	(i)             Payment
    of all fees and expenses required to be paid on the Closing Date pursuant to, and in accordance with, the Commitment Letter
    and Fee Letters entered into in connection herewith.
	 	 	 
	 	 	(ii)           Preparation,
    execution (as applicable) and delivery of (a) an intercreditor agreement with respect to the prime vendor agreement with AmerisourceBergen
    Drug Corporation (the “ABDC Intercreditor Agreement”) in form and substance satisfactory to the
    Lead Arrangers, (b) mutually acceptable and customary loan documentation (including, without limitation, a credit agreement
    for the Senior Credit Facilities) which shall (x) incorporate the terms and conditions set forth herein and in the Commitment
    Letter and such other terms and conditions as are not inconsistent with the terms and conditions set forth herein and therein
    and as the Borrower and the Administrative Agent and Lead Arrangers may agree, (y) be usual and customary for credit facilities
    of this type as reasonably determined by the Lead Arrangers, the Administrative Agent and the Borrower, and (z) give due regard
    to the operational requirements of the Credit Parties in light of their size, industry, practices, the Projections and the
    leverage profile of the Credit Parties as reasonably determined by the Lead Arrangers, the Administrative Agent and the Borrower
    (the provisions in clauses (x), (y) and (z) being collectively referred to herein as the “Documentation Considerations”),
    and (c) customary legal opinions, evidence of authorization, officer’s certificates with corporate documents attached,
    good standing certificates (to the extent applicable), lien searches, payoff letters and lien releases (specifically (1) including
    payoff letters and lien releases for the UCC financing statements filed by, with respect to the Borrower and its subsidiaries,
    Healthcare Finance Group, LLC, and (2) excluding Permitted Surviving Debt), officer’s certificates, certificates of
    insurance, flood determinations (if applicable), evidence of flood insurance (if applicable), material governmental and material
    third party consents and approvals for the Senior Credit Facilities (all of which shall be final, with no waiting period to
    expire or ongoing governmental inquiry or investigation), customary documents and instruments required to create and perfect
    the Administrative Agent’s first priority security interest (subject to Specified Permitted Liens) in the Collateral
    (which, if applicable, shall be in proper form for filing), and a customary solvency certificate of the Borrower’s chief
    financial officer or other appropriate responsible officer, in each case, in form and substance reasonably satisfactory to
    the Lead Arrangers.
	 	 	 
	 	 	(iii)           Delivery
    of documentation and information required by regulatory authorities under applicable “know your customer” and
    anti-money laundering laws at least five (5) business days prior to the Closing Date to the extent that such documentation
    and information was requested at least ten (10) days prior to the Closing Date.
	 	 	 
	 	 	(iv)           Delivery
    of (a) the consolidated audited financial statements of the Borrower and its subsidiaries for the fiscal year ended December
    31, 2012, including balance sheets, income and cash flow statements audited by independent public accountants of recognized
    national standing and prepared in conformity with GAAP in all material respects and (b) financial projections for the Borrower
    and its subsidiaries, after giving effect to the Senior Credit Facilities, for the five year period immediately following
    the Closing Date (including projections prepared on a quarterly basis through at least the end of the calendar year of 2013).

 

 

    	8

    	 

    

 

BioScrip, Inc.

 

	 	 	(v)            The
    Borrower shall have used commercially reasonable efforts to obtain credit ratings for the Senior Credit Facilities and the
    corporate family credit of the Borrower and its subsidiaries by S&P and Moody’s.
	 	 	 
	 	 	(vi)           Since
    December 31, 2012, the absence of a material adverse change in the business, condition (financial or otherwise), operations,
    liabilities (contingent or otherwise), or properties of the Borrower and its subsidiaries, on a consolidated basis and taken
    as a whole.
	 	 	 
	 	 	(vii)           With
    respect to the Borrower and its subsidiaries, the Specified Representations shall be true and correct in all material respects
    (or, in all respects, if qualified by materiality in the Financing Documentation).
	 	 	 
	 	 	(viii)           The
    Administrative Agent shall have received an executed notice of borrowing for the initial funding of the Senior Credit Facilities.  
	 	 	 
	Conditions to Delayed Draw Term
    Loan:	 	The availability of the Delayed Draw
    Term Loan on the Delayed Draw Date will be subject to the Certain Funds Provision in all respects and the satisfaction or
    waiver of solely the following conditions:
	 	 	 
	 	 	(i)           Since
    December 31, 2012, (a) the absence of any event, circumstance, development, condition, occurrence, state of facts, change
    or effect that, when considered individually or in the aggregate (1) is, or would reasonably be expected to be, materially
    adverse to the condition (financial or otherwise), business, assets, liabilities, operations or results of operations of CarePoint
    and its subsidiaries, taken as a whole, or (2) materially impairs the ability of CarePoint to consummate the transactions
    contemplated by the Acquisition Agreement, in either case, other than any event, circumstance, development, condition, occurrence,
    state of facts, change or effect arising out of:  (A) general business or economic conditions affecting the industry
    in which CarePoint and its subsidiaries operate, (B) national or international political or social conditions, including the
    engagement by the United States in hostilities or the escalation thereof, whether or not pursuant to the declaration of a
    national emergency or war, or the occurrence or the escalation of any military or terrorist attack upon the United States,
    or any of its territories, possessions or diplomatic or consular offices or upon any military installation, equipment or personnel
    of the United States, (C) financial, banking or securities markets (including any disruption thereof and any decline in the
    price of any security or any market index), (D) changes in GAAP, (E) changes in applicable law, (F) the taking of any action
    contemplated by the Acquisition Agreement or the other agreements contemplated thereby or the announcement of the Acquisition
    Agreement, the other agreements contemplated thereby or the transactions contemplated thereby, or (G) any adverse change in
    or effect on the business of CarePoint and its subsidiaries that is cured by or on behalf of CarePoint before the earlier
    of the Closing Date and the date on which the Acquisition Agreement is terminated pursuant to Article 7 of the Acquisition
    Agreement, and (b) the absence of a material adverse change in the business, condition (financial or otherwise), operations,
    liabilities (contingent or otherwise), or properties of the Borrower and its subsidiaries, on a consolidated basis and taken
    as a whole.  

 

    	9

    	 

    

 

BioScrip, Inc.

 

	 	 	(ii)           The
    Lead Arrangers shall have received (a) certified copies of the Acquisition Agreement (including the Company Disclosure Letter
    and any other schedules and exhibits thereto) and (b) evidence that the Acquisition shall have been consummated or, substantially
    simultaneously with the funding of the Delayed Draw Term Loan, shall be consummated in accordance with the terms of the Acquisition
    Agreement, without giving effect to any modifications, supplements, amendments, consents or waivers thereto that are material
    and adverse to any Lead Arranger or any Lender without the prior written consent of the Lead Arrangers (it being understood
    and agreed that (I) any decrease in the purchase price of less than 10% of the aggregate consideration payable in connection
    with the Acquisition shall be deemed to not be material or adverse to any Lead Arranger or any Lender, and (II) any increase
    in the purchase price shall be deemed to not be material or adverse to any Lead Arranger or any Lender so long as such increase
    is not funded with proceeds of the Senior Credit Facilities).
	 	 	 
	 	 	(iii)           The
    Specified Acquisition Agreement Representations shall be true and correct, and the Specified Representations shall be true
    and correct in all material respects (or, in all respects, if qualified by materiality in the Financing Documentation).
	 	 	 
	 	 	(iv)           The
    Administrative Agent shall have received an executed notice of borrowing for the Delayed Draw Term Loan.  
	 	 	 
	 	 	(v)            The
    advance of the Delayed Draw Term Loan will occur no later than October 31, 2013.
	 	 	 
	 	 	(vi)           Preparation,
    execution (as applicable) and delivery of customary lien searches, payoff letters and lien releases with respect to the Acquired
    Business (specifically, to the extent related to the Acquired Business and not related to liabilities or indebtedness that
    is retained by the Seller pursuant to the Acquisition Agreement, (1) including payoff letters and lien releases for the UCC
    financing statements filed by, with respect to the Acquired Business, Madison Capital Funding LLC, (2) including either (A)
    a payoff letter and lien release or (B) a UCC-3 financing statement amendment limiting the collateral description to purchased
    inventory, so long as the underlying obligations constitute Permitted Surviving Debt (whichever is required by the Lead Arrangers)
    of the UCC financing statement filed by ASD Specialty Healthcare Inc., (3) including either (A) a payoff letter and lien release,
    (B) a UCC-3 financing statement amendment limiting the collateral description to specific collateral, so long as the underlying
    obligations constitute Permitted Surviving Debt, or (C) other evidence satisfactory to the Lead Arrangers of termination of
    the underlying obligations (whichever is required by the Lead Arrangers) of the UCC financing statement filed by The Harvard
    Drug Group, L.L.C., and (4) excluding Permitted Surviving Debt), certificates of insurance, flood determinations (if applicable),
    evidence of flood insurance (if applicable), Hart-Scott-Rodino and other material governmental and material third party consents
    and approvals for the Acquisition (all of which shall be final, with no waiting period to expire or ongoing governmental inquiry
    or investigation), customary documents and instruments required to create and perfect the Administrative Agent’s first
    priority security interest (subject to Specified Permitted Liens) in the Collateral acquired pursuant to the Acquisition (which,
    if applicable, shall be in proper form for filing), and customary documents to join any subsidiary acquired or formed in connection
    with the Acquisition to the Financing Documentation as a Guarantor (to the extent that such subsidiary would have been required
    to be a Guarantor on the Closing Date), in each case, in form and substance reasonably satisfactory to the Lead Arrangers.

 

    	10

    	 

    

 

BioScrip, Inc.

 

	 	 	(vii)           Delivery
    of (a) the consolidated audited financial statements of CarePoint and its subsidiaries for the fiscal years ended December
    31, 2010, December 31, 2011, and December 31, 2012, including balance sheets, income and cash flow statements audited by independent
    public accountants of recognized national standing and prepared in conformity with GAAP in all material respects, and (b)
    the consolidated unaudited financial statements of CarePoint and its subsidiaries for the fiscal quarter ended December 31,
    2012, and for each subsequent fiscal quarter for which financial statements are available.
	 	 	 
	Conditions to All Other Credit
    Extensions:	 	Each credit extension under the Senior
    Credit Facilities after the Closing Date (other than the advance of the Delayed Draw Term Loan) will be subject to the following
    conditions:  receipt of a notice of borrowing; accuracy of representations and warranties in all material respects;
    absence of any default or event of default; and with respect to any Letter of Credit or Swingline Loan, no defaulting lender
    in existence (unless cash collateral has been posted, such defaulting lender’s revolving commitment has been reallocated,
    or other arrangements reasonably satisfactory to the Swingline Lender or Issuing Bank, as applicable, have been made).
	 	 	 
	Representations and Warranties:	 	The Financing Documentation will contain
    only the following representations and warranties applicable to the Credit Parties and their subsidiaries (with customary
    and reasonable qualifications, exceptions and thresholds to be agreed upon and subject to the Documentation Considerations):  due
    organization, good standing, power and authority; due authorization, execution, delivery and enforceability; governmental
    and third party consents and approvals; no violation of laws, regulations, judgments, organizational documents, or material
    agreements; health care matters; HIPAA compliance; reimbursement from governmental and third party payors; no fraud or abuse;
    reimbursement policies; management services agreements; no creation of liens; accuracy of financial statements; absence of
    any material adverse change; no litigation; environmental matters; compliance with material agreements; not an investment
    company or subject to regulation restricting the incurrence of indebtedness; tax matters; margin regulations; use of proceeds;
    ERISA; ownership of assets; insurance; intellectual property; accuracy of disclosure; labor matters; subsidiaries and equity
    interests; deposit and disbursement accounts; solvency; creation, perfection, and priority of security interests; Patriot
    Act, OFAC, FCPA and anti-money laundering law compliance.

 

    	11

    	 

    

 

BioScrip, Inc.

 

	Covenants:	 	The Financing Documentation
    will contain only the following covenants applicable to the Credit Parties and their subsidiaries (with customary and reasonable
    qualifications, exceptions and thresholds to be agreed upon and subject to the Documentation Considerations):
	 	 	 
	 	 	(a)           Reporting
    Covenants - Delivery of annual audited financial statements, budgets and forecasts; quarterly unaudited financial statements;
    accountant’s certificate from nationally recognized auditors with annual financials containing an opinion that is not
    subject to any qualification as to “going concern” or scope of the audit (except as it relates to the impending
    maturity of the Senior Credit Facilities); copies of materials filed with the SEC; copies of environmental reports with respect
    to owned real property that constitutes Collateral; other information reasonably requested by the Administrative Agent or
    any Lender; quarterly compliance certificates; customary notifications, including, without limitation, notice of any default,
    material litigation, material environmental liabilities, material ERISA events, any default or material amendment under, or
    termination of, the Facility Participation Agreement with United HealthCare Insurance Company, contracting on behalf of its
    Oxford Health Plans (NJ), the Facility Participation Agreement with United HealthCare Insurance Company, contracting on behalf
    of itself and UnitedHealthcare of the Midwest, the Ancillary Provider Participation Agreement with United HealthCare Insurance
    Company, contracting on behalf of itself and UnitedHealthcare of New York, or the Ancillary Provider Participation Agreement
    with UnitedHealthcare of New York, Inc., final audit reports and final management letters, healthcare matters, and changes
    to any Credit Party’s legal name, chief executive office, legal structure, jurisdiction of organization, or taxpayer
    number.  Delivery of annual audited financial statements and quarterly unaudited financial statements may be satisfied
    by delivering the Borrower’s Form 10-K or 10-Q filed with the SEC, within the applicable time periods for delivery of
    such statements, as applicable, set forth in the Financing Documentation.  
	 	 	 
	 	 	(b)           Affirmative
    Covenants - maintenance of existence, property, insurance, material intellectual property, material licenses and permits,
    corporate separateness, and credit ratings; conduct of business; compliance with laws; payment of taxes and other obligations;
    books and records; inspection rights; use of proceeds; margin regulations; casualty and condemnation; landlord agreements
    and other real property matters (including without limitation, to the extent any mortgages are provided, satisfaction of all
    flood insurance requirements of the Lenders); health care matters; environmental matters; accounting systems; cash management
    systems and deposit accounts; designation as senior debt; additional subsidiaries, guaranties, and pledges of equity interests;
    additional collateral; further assurances; post-closing covenants (if any).

 

 

    	12

    	 

    

 

BioScrip, Inc.

 

	 		(c)           Negative
    Covenants - Restrictions on indebtedness (with exceptions for, among others, (1) purchase money indebtedness and capital
    leases, (2) unsecured seller debt incurred in connection with Permitted Acquisitions, (3) intercompany indebtedness and (4)
    additional secured and unsecured indebtedness (subject to terms, baskets and Total Net Leverage Ratio thresholds to be mutually
    agreed and, in the case of secured indebtedness, an intercreditor agreement in form and substance satisfactory to the Administrative
    Agent); liens; mergers, consolidations, and acquisitions (with exceptions for, among others, Permitted Acquisitions); sale
    of assets; engaging in business other than current business and those reasonably related, incidental and ancillary thereto;
    investments and loans (with exceptions for, among others, Permitted Acquisitions, joint ventures and intercompany advances
    subject to terms and baskets to be mutually agreed; provided, that investments in and loans to subsidiaries that are not Guarantors
    shall be limited as mutually agreed); redemptions and payments on junior debt and junior capital; affiliate transactions (with
    exceptions for, among others, arms’ length transactions); covenants limiting dividends, management fees and loans (with
    exceptions for, among others, cash dividends and distributions, in each case, subject to limitations to be agreed); restrictive
    agreements; margin stock; sale/leaseback transactions; speculative hedging; amendments to organizational documents; amendments
    to material agreements that are adverse to the Lenders in any material respect; change in fiscal year or accounting practices;
    government regulation; health care matters; ERISA. 
	 	 	 
	 		(d)           Permitted
    Acquisitions – Borrower and its subsidiaries will be permitted to make (1) the Acquisition and (2) other acquisitions,
    subject to the satisfaction or waiver by the Administrative Agent of the following conditions (each, a “Permitted
    Acquisition”): (i) delivery of a description of the proposed acquisition and, to the extent available, any letters
    of intent or term sheets with respect to such acquisition and financial statements for the target, in each case, at least
    10 business days prior to the closing of such acquisition and, at least three business days prior to the closing of any acquisition
    for an aggregate cash consideration of more than an amount to be mutually agreed, copies of substantially final versions of
    the documentation evidencing such acquisition; (ii) receipt of all material regulatory and third party approvals with respect
    to such acquisition; (iii) granting to the Administrative Agent of a first priority security interest (subject to permitted
    liens) in all acquired assets (to the extent constituting Collateral) as may be required by the Financing Documentation, subject
    to customary exceptions; (iv) no existing default or event of default under the Senior Credit Facilities and continuing compliance,
    on a pro forma basis after giving effect to the acquisition and any indebtedness incurred in connection therewith, with all
    covenants; (v) evidence that the Total Net Leverage Ratio is less than or equal to 5.50 to 1.00, and the Senior Secured Net
    Leverage Ratio (as defined below) is less than or equal to 5.00 to 1.00, in each case, on a pro forma basis after giving effect
    to the acquisition and any indebtedness incurred in connection therewith, as of the last day of the most recent fiscal quarter
    for which financial statements are required to have been delivered pursuant to the Financing Documentation; (vi) the proposed
    acquisition is consensual (not “hostile”), and, if applicable, has been approved by the acquisition target’s
    board of directors or other similar governing body; and (vii) any entity acquired pursuant to such acquisition shall become
    a Guarantor to the extent that such entity would have been required to be a Guarantor on the Closing Date.

 

    	13

    	 

    

 

BioScrip, Inc.

 

	 	 	(e)           Financial
    Covenants - Maintenance of the following financial covenant (with levels and definitions to be determined):
	 	 	 
	 	 	With respect to the Term B Loans:  None.
    
	 	 	 
	 	 	With respect to the Revolver: So long
    as a Revolver Covenant Triggering Event (as defined below) has occurred and is continuing, a Senior Secured Net Leverage Ratio
    solely for the benefit of the Lenders under the Revolver as set forth below: 
	 	 	 
	 	 	Senior Secured
    Net Leverage Ratio – As of the last day of any fiscal
    quarter after the occurrence and during the continuance of a Revolver Covenant Triggering Event, the ratio of (i) the sum
    of total consolidated funded debt2 (other than
    any subordinated debt and unsecured debt not prohibited by the Financing Documentation and less unrestricted cash and cash
    equivalents (for the avoidance of doubt, excluding proceeds of any loans being made on the date that the Senior Secured Net
    Leverage Ratio is tested)) on such date to (ii) Consolidated EBITDA for the four consecutive fiscal quarters ending on such
    date shall not exceed a maximum ratio to be specified in the Financing Documentation.  The covenant levels shall
    be set with a 35% cushion off of the levels provided in management’s base case model prepared for the initial funding
    under the Senior Credit Facilities.
	 	 	 
	 	 	Any amendment, waiver or modification
    of the Senior Secured Net Leverage Ratio shall only require the vote of the Lenders holding at least a majority of the commitments
    under the Revolver. An event of default as a result of the breach of the Senior Secured Net Leverage Ratio shall only result
    in a default or an event of default with respect to the Term B Loans if the Lenders under the Revolver have terminated the
    commitments under the Revolver and accelerated any loans then outstanding thereunder. 
	 	 	 
	 	 	The Senior Secured Net Leverage Ratio
    covenant will be tested each fiscal quarter solely to the extent that, on the last day of such fiscal quarter the outstanding
    principal amount of advances drawn under the Revolver exceeds 25% of the maximum amount able to be drawn under the Revolver
    (a “Revolver Covenant Triggering Event”). 

 

 

2 Consolidated funded debt to exclude
any obligations owed by the Credit Parties to AmerisourceBergen Drug Corporation under the Prime Vendor Agreement.

 

    	14

    	 

    

 

BioScrip, Inc.

 

	 	 	For purposes of this Term
    Sheet, “Consolidated EBITDA” will be defined as mutually agreed.  
	 	 	 
	Events of Default:	 	The Financing Documentation will contain
    only the following events of default (with customary and reasonable qualifications, exceptions and thresholds to be agreed
    upon and subject to the Documentation Considerations): payment default; breach of representations in any material respect;
    in respect of the Revolver only, breach of the Senior Secured Net Leverage Ratio financial covenant (to the extent applicable)
    (provided that a breach shall only result in a default or an event of default with respect to the Term B Loans if the Lenders
    under the Revolver have terminated the commitments under the Revolver and accelerated any loans then outstanding thereunder);
    breach of other covenants or events of default in the Financing Documentation; cross-default to material indebtedness; cross-default
    to AmerisourceBergen Drug Corporation second lien obligations; bankruptcy; inability to generally pay debts as they become
    due; commencement of any governmental proceeding or hearing relating to, or any involuntary termination of, any license, consent,
    authorization, accreditation, reimbursement approval, permit, or certificate, to the extent such proceeding or hearing would
    reasonably be expected to have a material adverse effect; ERISA; material judgments; change in control; termination or invalidity
    of the ABDC Intercreditor Agreement or any other loan document or any material portion thereof; invalidity of first priority
    security interest (subject to Specified Permitted Liens) in Collateral; criminal conviction that would reasonably be expected
    to lead to forfeiture of a material portion of Collateral or exclusion from participation in any federal or state health care
    plan.  
	 	 	 
	Participations and Assignments:	 	Assignments of the Senior Credit Facilities
    to other banks, financial institutions and funds will be permitted with the written approval of the Borrower and the Administrative
    Agent (such approval not to be unreasonably withheld or delayed, and such approval not required by Borrower if an event of
    default has occurred) in minimum amounts of $5,000,000 with respect to the Revolver and $1,000,000 with respect to the Term
    B Loans, and minimum increments of $1,000,000; provided, however, that (i) no such consent of the Borrower or
    the Administrative Agent shall be required to any assignment of any Loan by a Lender to an affiliate of such Lender or to
    a debt fund managed by a Lender or an affiliate of a Lender, (ii) the minimum increment requirement shall not apply if a Lender
    is assigning its entire commitment and (iii) no Lender shall be permitted to assign any portion of the Senior Credit Facilities
    to a Disqualified Institution and any refusal by the Borrower to consent to an assignment to a Disqualified Institution shall
    not be deemed to be unreasonable; provided, further, that Borrower shall be deemed to have consented to any
    such assignment unless it objects thereto by written notice to the Administrative Agent within 5 business days after having
    received notice thereof.  An administrative fee of $3,500 shall be due and payable by such assigning Lender to the
    Administrative Agent upon the occurrence of any assignment.  Participations to other banks and financial institutions
    (other than Competitors) will be permitted without consent but will not release the selling Lender from its obligations with
    respect to the Senior Credit Facilities.  For the avoidance of doubt, no Credit Party nor any affiliate of a Credit
    Party shall be a Lender under the Senior Credit Facilities.  

 

    	15

    	 

    

 

BioScrip, Inc.

 

	Waivers and Amendments:	 	Amendments and waivers
    will require approval of Lenders holding more than 50% of the loans and commitments under the Senior Credit Facilities (the
    “Required Lenders”), except that the consent of each affected Lender shall be required to, among
    other things, (i) extend or increase any commitment, or extend the date scheduled for payment of any principal (excluding
    any mandatory prepayment), interest or fees, (ii) reduce the principal amount of any loan, the rate of interest under any
    loan or fees payable in respect of any loan, (iii) release all or substantially all of the Collateral or all or substantially
    all of the value of any guaranty, (iv) change the waterfall provisions, or pro rata sharing and payment provisions, and (v)
    reduce the percentage required for “Required Lenders”; provided that the Financing Documentation shall
    provide the right for any individual Lender to agree to extend the maturity date and/or extend the commitment expiration date
    of its portion of the Revolver upon the request of Borrower without the consent of any other Lender on terms and conditions
    to be mutually agreed and pursuant to pro rata offers for the applicable class.
	 	 	 
	Replacement Lenders:	 	The Financing
    Documentation will contain customary provisions for replacing any Lender that (i) is a defaulting lender, (ii) has requested
    reimbursement for increased costs or required tax gross ups, or (iii) withholds its consent to certain amendments or waivers
    with respect to which such Lender’s consent was required; provided that such amendments or waivers have been approved
    by the Required Lenders.
	 	 	 
	Defaulting Lenders:	 	Defaulting lenders will not be entitled
    to commitment fees, will be excluded for purposes of determining Required Lenders and will be subject to removal at par.  Amounts
    owed to defaulting lenders will be subject to setoff for amounts not funded, and Swingline Lender and Issuing Bank will be
    relieved of any obligation to issue new Letters of Credit or fund Swingline Loans unless and until satisfactory arrangements
    have been made to eliminate risk to Swingline Lender or Issuing Bank, as appropriate, with respect to the participation in
    Swingline Loans or Letters of Credit, as appropriate, of the defaulting lender, including by cash collateralizing such defaulting
    lender’s pro rata share of the Swingline Loan and Letter of Credit exposure.

 

    	16

    	 

    

 

BioScrip, Inc.

 

	Indemnification:	 	The Borrower will indemnify
    and hold harmless the Administrative Agent, each Lead Arranger, the Issuing Bank, the Swingline Lender, each Lender and their
    respective affiliates and their partners, directors, officers, employees, agents and advisors from and against all losses,
    claims, damages, liabilities and expenses arising out of or relating to the Senior Credit Facilities and the other Transactions
    contemplated by the Financing Documentation, the Borrower’s use of loan proceeds or the commitments, including, but
    not limited to reasonable and documented attorney’s fees, expenses and settlement costs; provided that the Borrower
    shall not be liable to any indemnified person pursuant to this indemnity for any amounts to the extent that a court having
    competent jurisdiction shall have determined by a final judgment (not subject to further appeal) that such amount resulted
    from (a) the bad faith, gross negligence or willful misconduct of such indemnified person or (b) a material breach by such
    indemnified person of any of its undertakings, obligations or commitments under the Financing Documentation.  This
    indemnification shall survive and continue for the benefit of all such persons and entities.
	 	 	 
	Governing Law:	 	State of New York.
	 	 	 
	Counsel to the Administrative Agent:	 	Jones Day.
	 	 	 
	Miscellaneous:	 	Each party shall waive its right to
    a trial by jury and submit to jurisdiction in New York.  The Financing Documentation will contain customary increased
    cost, withholding tax, capital adequacy and yield protection provisions.

 

    	17

    	 

    

 

BioScrip, Inc.

 

ADDENDUM I

 

PRICING, FEES AND EXPENSES

 

Capitalized terms not otherwise defined
in this Addendum have the meaning set forth in the Summary of Principal Terms and Conditions to which this Addendum is attached.

 

	Interest Rates:	 	The interest rates per
    annum applicable to the Senior Credit Facilities (other than with respect to Swingline Loans) will be, at the option of the
    Borrower, (i) LIBOR plus the Applicable Margin (as defined below), or (ii) the Base Rate plus the Applicable
    Margin.
	 	 	 
	 	 	LIBOR
    means, for any interest period of 1, 2, 3 or 6 months (or, with the consent of all applicable Lenders, 9 or 12 months), the
    rate per annum appearing on Reuters Screen LIBOR01 Page as the London interbank offered rate for deposits in Dollars at approximately
    11:00 a.m. (London time) two business days prior to the first day of such interest period for a term comparable to such Interest
    Period.  If for any reason such rate is not available, LIBOR shall be, for any such interest period, the rate per
    annum reasonably determined by the Administrative Agent as the rate of interest at which Dollar deposits in the approximate
    amount of the LIBOR loan comprising part of such borrowing would be offered by the Administrative Agent to major banks in
    the London interbank Eurodollar market at or about 10:00 a.m. (Atlanta, Georgia time) two business days prior to the first
    day of such Interest Period for a term comparable to such Interest Period.  LIBOR shall be adjusted for applicable
    reserve requirements.  LIBOR on the Initial Term B Loan and the Delayed Draw Term Loan shall be subject to a 1.00%
    LIBOR floor.
	 	 	 
		 	Base Rate
    means the highest of (i) the rate which SunTrust announces from time to time as its prime lending rate, as in effect from
    time to time, (ii) the Federal Funds rate, as in effect from time to time, plus one-half of one percent (1⁄2%) per annum
    (any changes in such rates to be effective as of the date of any change in such rate), or (iii) LIBOR determined on a daily
    basis for a period of one month plus 1.00%.  The SunTrust prime lending rate is a reference rate and does not necessarily
    represent the lowest or best rate actually charged to any customer.  SunTrust may make commercial loans or other
    loans at rates of interest at, above, or below the SunTrust prime lending rate.
	 	 	 
	 	 	Applicable Margin
    means (a) with respect to the Initial Term B Loan and
    the Delayed Draw Term Loan, a percentage per annum equal to (i) 4.50% with respect to LIBOR loans and (ii) 3.50% with respect
    to Base Rate loans and (b) with respect to the Revolver, an initial percentage per annum equal to (i) 4.25% with respect to
    LIBOR loans and (ii) 3.25% with respect to Base Rate loans, subject in the case of this clause (b) to a mutually agreed pricing
    table based on the Total Net Leverage Ratio.
	 	 	 
	 	 	Each Swingline Loan shall bear interest
    at the Base Rate plus the Applicable Margin for Base Rate loans under the Revolver.

 

    	18

    	 

    

 

BioScrip, Inc.

 

	 	 	Interest for LIBOR loans
    shall be payable at the end of the selected interest period but no less frequently than quarterly.  Interest for
    Base Rate Loans and Swingline Loans shall be payable quarterly in arrears.
	 	 	 
	Default Interest:	 	If any Triggering Event of Default
    has occurred and is continuing, at the written request of the Required Lenders, the then otherwise applicable Applicable Margin
    and Letter of Credit Fees shall be increased by 2% per annum; provided that, for any LIBOR advances, at the end of the applicable
    Interest Period, interest shall accrue at the Base Rate plus the Applicable Margin plus 2% per annum.  Default interest
    shall be payable on demand.
	 	 	 
	 	 	For purposes of this Term Sheet, “Triggering
    Event of Default” shall mean a payment or bankruptcy event of default.
	 	 	 
	Commitment Fee:	 	A commitment fee of 0.50% per annum
    shall be payable by the Borrower quarterly in arrears on the average daily unused portion of the Revolver.  Outstanding
    Letters of Credit under the Revolver will be deemed usage of the Revolver, but loans under the Swingline shall not be deemed
    usage of the Revolver.
	 	 	 
	Delayed Draw Ticking Fee:	 	A delayed draw ticking fee (the “Delayed
    Draw Ticking Fee”) shall be payable by the Borrower quarterly in arrears on the average daily undrawn portion
    of the Delayed Draw Term Loan.  Such ticking fee shall begin to accrue on the date that is 31 days after the Closing
    Date.  The Delayed Draw Ticking Fee shall be in an amount equal to (a) for the period from and including the 31st
    day after the Closing Date through and including the 90th day after the Closing Date, 0.50 multiplied
    by the Applicable Margin for LIBOR loans under the Term B Loans and (b) for the period from and including the 91st
    day after the Closing Date and continuing thereafter (subject to the following sentence), the Applicable Margin for
    LIBOR loans under the Term B Loans.  Such ticking
    fee shall cease to accrue on the earliest of (i) the Delayed Draw Date, (ii) the date on which the Delayed Draw Term Loan
    commitment is terminated in writing by the Borrower and (iii) October 31, 2013.  
	 	 	 
	Letter of Credit Fee:	 	Letter of Credit fees shall be payable
    quarterly in arrears at a rate equal to the Applicable Margin for LIBOR loans under the Revolver on the average outstanding
    Letters of Credit, ratably to the Lenders in accordance with their participation in the respective Letters of Credit.  In
    addition, a facing fee and other customary administrative charges shall be paid to the Issuing Bank for its own account.  In
    each case, fees shall be calculated on the aggregate stated amount of the Letters of Credit for the duration of the Letters
    of Credit.
	 	 	 
	Calculation of Interest and
    Fees:	 	Other than calculations in respect
    of interest at the SunTrust prime rate (which shall be made on the basis of actual number of days elapsed in a 365/366 day
    year), all calculations of interest and fees shall be made on the basis of actual number of days elapsed in a 360-day year.  

 

    	19

    	 

    

 

BioScrip, Inc.

 

	Cost and Yield Protection:	 	Customary for transactions
    and facilities of this type, including, without limitation, in respect of payment of withholding tax “gross-up”
    amounts; suspension of LIBOR pricing option due to illegality or inability to ascertain funding costs; payment of reserve
    requirements, increased funding costs and capital adequacy compensation; payment of breakage and redeployment costs in connection
    with fundings and repayments of LIBOR advances; and payments resulting from any change in law; provided, that (a) the Dodd-Frank
    Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection
    therewith and (b) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the
    Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory
    authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “change in law”, regardless
    of the date enacted, adopted or issued.
	 	 	 
	Expenses:	 	The Borrower will pay all reasonable
    and documented costs and expenses of the Administrative Agent, STRH, SunTrust Bank, Jefferies, and Morgan Stanley associated
    with the preparation, due diligence, audits, third party consultants, administration, syndication and closing of the Financing
    Documentation, including, without limitation, with respect to the Administrative Agent, STRH, and SunTrust Bank only, the
    reasonable and documented fees, disbursements, and expenses of one outside counsel (and any required special or local counsel),
    in each case, regardless of whether the Senior Credit Facilities are closed.  The Borrower will also pay the documented
    expenses of the Administrative Agent and each Lender (including, without limitation, documented fees and disbursements one
    outside counsel to each such party (and any required special or local counsel to each such party)) in connection with the
    enforcement of any of the Financing Documentation.

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]